[Xingqi Eye Drops: company Travoprost Eye Drops obtains Drug Registration Certificate] May 9, Xingqi Eye Drops announcement, recently, the company received the "Drug Registration Certificate" of travoprost eye drops approved and issued by the State Drug Administration. The travoprost eye drops approved by the company is a single-dose product without bacteriostasis. the clinical indication is to reduce the intraocular pressure of adult patients with open-angle glaucoma or ocular hypertension. At present, three travoprost eye drops imitation pharmaceuticals have been listed in China, all of which are multi-dose products containing antimicrobial agents.